## Philip S J Weston

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7676223/publications.pdf

Version: 2024-02-01

516710 477307 1,375 47 16 29 citations g-index h-index papers 50 50 50 2873 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Serum neurofilament light in familial Alzheimer disease. Neurology, 2017, 89, 2167-2175.	1.1	204
2	Clinical phenotype and genetic associations in autosomal dominant familial Alzheimer's disease: a case series. Lancet Neurology, The, 2016, 15, 1326-1335.	10.2	163
3	Molecular biomarkers of Alzheimer's disease: progress and prospects. DMM Disease Models and Mechanisms, $2018,11,.$	2.4	163
4	Diffusion imaging changes in grey matter in Alzheimer's disease: a potential marker of early neurodegeneration. Alzheimer's Research and Therapy, 2015, 7, 47.	6.2	132
5	Accelerated long-term forgetting in presymptomatic autosomal dominant Alzheimer's disease: a cross-sectional study. Lancet Neurology, The, 2018, 17, 123-132.	10.2	84
6	Cerebrospinal fluid in the differential diagnosis of Alzheimer's disease: clinical utility of an extended panel of biomarkers in a specialist cognitive clinic. Alzheimer's Research and Therapy, 2018, 10, 32.	6.2	79
7	Plasma phospho-tau181 in presymptomatic and symptomatic familial Alzheimer's disease: a longitudinal cohort study. Molecular Psychiatry, 2021, 26, 5967-5976.	7.9	76
8	Longitudinal measurement of serum neurofilament light in presymptomatic familial Alzheimer's disease. Alzheimer's Research and Therapy, 2019, 11, 19.	6.2	65
9	Factors Associated With the Onset and Persistence of Post–Lumbar Puncture Headache. JAMA Neurology, 2015, 72, 325.	9.0	59
10	Presymptomatic cortical thinning in familial Alzheimer disease. Neurology, 2016, 87, 2050-2057.	1.1	58
11	Transitioning from cerebrospinal fluid to blood tests to facilitate diagnosis and disease monitoring in Alzheimer's disease. Journal of Internal Medicine, 2021, 290, 583-601.	6.0	54
12	The use of mini-CEX in UK foundation training six years following its introduction: Lessons still to be learned and the benefit of formal teaching regarding its utility. Medical Teacher, 2014, 36, 155-163.	1.8	48
13	Direct Parametric Reconstruction With Joint Motion Estimation/Correction for Dynamic Brain PET Data. IEEE Transactions on Medical Imaging, 2017, 36, 203-213.	8.9	25
14	Discrimination of voice gender in the human auditory cortex. Neurolmage, 2015, 105, 208-214.	4.2	23
15	Diagnosing Dementia in the Clinical Setting: Can Amyloid PET Provide Additional Value Over Cerebrospinal Fluid?. Journal of Alzheimer's Disease, 2016, 54, 1297-1302.	2.6	21
16	Measuring cortical mean diffusivity to assess early microstructural cortical change in presymptomatic familial Alzheimer's disease. Alzheimer's Research and Therapy, 2020, 12, 112.	6.2	18
17	Using florbetapir positron emission tomography to explore cerebrospinal fluid cut points and gray zones in small sample sizes. Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 440-446.	2.4	16
18	Plasma amyloid-β ratios in autosomal dominant Alzheimer's disease: the influence of genotype. Brain, 2021, 144, 2964-2970.	7.6	16

#	Article	IF	CITATIONS
19	Quantitative detection and staging of presymptomatic cognitive decline in familial Alzheimer's disease: a retrospective cohort analysis. Alzheimer's Research and Therapy, 2020, 12, 126.	6.2	13
20	Reduced acquisition time PET pharmacokinetic modelling using simultaneous ASL–MRI: proof of concept. Journal of Cerebral Blood Flow and Metabolism, 2019, 39, 2419-2432.	4.3	11
21	Processing of Self versus Non-Self in Alzheimer's Disease. Frontiers in Human Neuroscience, 2016, 10, 97.	2.0	9
22	Longitudinal ( <sup>18</sup> F)AV-1451 PET imaging in a patient with frontotemporal dementia due to a Q351R MAPT mutation. Journal of Neurology, Neurosurgery and Psychiatry, 2020, 91, 106-108.	1.9	8
23	Visuomotor integration deficits are common to familial and sporadic preclinical Alzheimer's disease. Brain Communications, 2021, 3, fcab003.	3.3	8
24	Visual short-term memory impairments in presymptomatic familial Alzheimer's disease: A longitudinal observational study. Neuropsychologia, 2021, 162, 108028.	1.6	7
25	Do cerebrospinal fluid transfer methods affect measured amyloid $\hat{l}^2$ 42, total tau, and phosphorylated tau in clinical practice? Alzheimer's and Dementia: Diagnosis, Assessment and Disease Monitoring, 2015, 1, 380-384.	2.4	5
26	P2-144: Model-Based Comparison of Autosomal-Dominant and Late-Onset Alzheimer's Disease Progression in the Dian and ADNI Studies. , 2016, 12, P668-P669.		4
27	O2-04-05: Accelerated Long-Term Forgetting in Presymptomatic Familial Alzheimer's Disease. , 2016, 12, P231-P231.		2
28	Metastatic bladder transitional cell carcinoma presenting as a vascularised cutaneous right arm lesion. International Journal of Clinical Oncology, 2012, 17, 286-289.	2,2	1
29	[P2–458]: VISUOMOTOR INTEGRATION IN PRESYMPTOMATIC FAMILIAL ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P815.	0.8	1
30	P1â€524: VISUAL SHORTâ€ŢERM BINDING DEFICIT IN FAMILIAL ALZHEIMER'S DISEASE: A LONGITUDINAL STUDY. Alzheimer's and Dementia, 2018, 14, P532.	0.8	1
31	O3â€03â€01: THE SEQUENCE AND TIMING OF PRECLINICAL COGNITIVE DECLINE IN AUTOSOMAL DOMINANT ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2019, 15, P882.	0.8	1
32	IC-P-175: LONGITUDINAL VOLUMETRIC AND DIFFUSION TENSOR IMAGING IN FAMILIAL ALZHEIMER'S DISEASE. , 2014, 10, P97-P98.		0
33	O1-07-02: LONGITUDINAL VOLUMETRIC AND DIFFUSION TENSOR IMAGING IN FAMILIAL ALZHEIMER'S DISEASE. , 2014, 10, P141-P142.		O
34	IC-P-117: A cortical signature of familial Alzheimer's disease: Cross-sectional and longitudinal study of presymptomatic changes., 2015, 11, P80-P81.		0
35	P1-191: Using florbetapir F18 PET to validate CSF cut-points and increase diagnostic certainty in atypical dementias., 2015, 11, P421-P422.		O
36	IC-P-118: Measurement of cortical mean diffusivity detects early microstructural breakdown of the cerebral cortex in presymptomatic familial Alzheimer's disease., 2015, 11, P81-P81.		0

#	Article	IF	CITATIONS
37	O2-01-05: A cortical signature of familial Alzheimer's disease: Cross-sectional and longitudinal study of presymptomatic changes. , 2015, 11, P173-P174.		0
38	F5â€02â€02: Longitudinal Atrophy in Autosomal Dominant Ad and Sporadic Ad: Lessons from Dian. Alzheimer's and Dementia, 2016, 12, P368.	0.8	0
39	[ICâ€Pâ€150]: CHARACTERISING PRESYMPTOMATIC ATROPHY PATTERNS THROUGH MULTIVARIATE MACHINE LEARNING. Alzheimer's and Dementia, 2017, 13, P113.	0.8	0
40	[P2–241]: CSF NEUROGRANIN IS INCREASED IN FAMILIAL ALZHEIMER's DISEASE. Alzheimer's and Dementia, 2017, 13, P703.	0.8	0
41	[O1–02–02]: CHARACTERISING PRESYMPTOMATIC ATROPHY PATTERNS THROUGH MULTIVARIATE MACHINE LEARNING. Alzheimer's and Dementia, 2017, 13, P185.	0.8	0
42	[F4–01–04]: NEUROIMAGING AND HETEROGENEITY IN FAMILIAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2017, 13, P1211.	0.8	0
43	[O4–02–04]: SERUM NEUROFILAMENT LIGHT CONCENTRATION IN FAMILIAL ALZHEIMER's DISEASE AND ASSOCIATION WITH MARKERS OF DISEASE STAGE AND SEVERITY. Alzheimer's and Dementia, 2017, 13, P1230.	0.8	0
44	O2â€04â€04: LONGITUDINAL MEASUREMENT OF SERUM NEUROFILAMENT LIGHT CONCENTRATION IN FAMILIAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P623.	0.8	0
45	P3â€261: SERUM NEUROFILAMENT LIGHT CONCENTRATION AND PROGRESSION IN FAMILIAL ALZHEIMER'S DISEASE. Alzheimer's and Dementia, 2018, 14, P1174.	0.8	0
46	Plasma phosphoâ€tau in familial Alzheimer's disease. Alzheimer's and Dementia, 2020, 16, e042921.	0.8	0
47	Accelerated longâ€ŧerm forgetting: Prognostic utility in familial Alzheimer's disease. Alzheimer's and Dementia, 2021, 17, .	0.8	0